Open tender · Germany · Contract notice

Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Edoxaban, ATC B01AF03 für die Zeit 01.04.2025 - 31.03.2026 (zzgl. Verlängerungsoption 1 x 12 Monate)

DAK-Gesundheit

DAK-Gesundheit in Germany is inviting bids for “Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Edoxaban, ATC B01AF03 für die Zeit 01.04.2025 - 31.03.2026…”. Bids close on 5 February 2027. To qualify, bidders need at least one similar completed work and DAK-Gesundheit contractual terms.

The work

Conclusion of a non-exclusive discount agreement for the active substance Edoxaban (ATC B01AF03) for the period 01.04.2025 - 31.03.2026 with an option for one 12-month extension.

  • Agreement must be concluded for medicinal products containing Edoxaban, ATC B01AF03
  • Contract must include predefined discounts set by DAK-Gesundheit

Key facts

Contract period
01.04.2025 - 31.03.2026 (+ 1 x 12 month extension option)
Evaluation
Lowest price (L1) among technically qualified bids
Submission
Online, on the e-procurement portal

What it takes to qualify

Worth a closer look

  • The tender uses the form for 'Offene Verfahren' although it states it is not an open procedure but a 'Zulassungsverfahren'.

Experience

  • At least 1 similar work — Similar pharmaceutical rebate agreements for ATC B01AF03
  • Experience in concluding framework discount agreements (Rabattvereinbarungen) for pharmaceuticals

Certifications and registrations

DAK-Gesundheit contractual termsAcknowledgment of DAK-Gesundheit's contractual terms, especially predefined discounts
GST registration (optional)

Policy conditions

No reservation, preference or local-content restriction.

Documents to submit

  1. AngebotsschreibenIncludes declaration that no exclusion criteria under §§ 123 and 124 GWB apply
  2. VertragSigned contract with company name or seal acknowledging DAK-Gesundheit's terms
  3. Anlage 1Filled-out annex 1 to the contract
  4. Anlage 2Excel file listing the specific medicinal products for the contract